Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.

Mankikian, Julie; Caille, Agnès; Reynaud-Gaubert, Martine; Agier, Marie-Sara; Bermudez, Julien; Bonniaud, Philippe; Borie, Raphael; Brillet, Pierre-Yves; Cadranel, Jacques; Court-Fortune, Isabelle; Crestani, Bruno; Debray, Marie-Pierre; Gomez, Emmanuel; Gondouin, Anne; Hirschi-Santelmo, Sandrine; Israel-Biet, Dominique; Jouneau, Stéphane; Juvin, Karine; Leger, Julie; Kerjouan, Mallorie; Marquette, Charles-Hugo; Naccache, Jean-Marc; Nunes, Hilario; Plantier, Laurent; Prevot, Grégoire; Quetant, Sébastien; Traclet, Julie; Valentin, Victor; Uzunhan, Yurdagul; Wémeau-Stervinou, Lidwine; Bejan-Angoulvant, Theodora; Cottin, Vincent; Marchand-Adam, Sylvain; investigators and the OrphaLung network, EVER-ILD

doi:10.1183/13993003.02071-2022

Public

Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.

Shared by NobleBlocks on Jun 1, 2023 • 12:00 AM UTC

Authors:

Julie Mankikian

Agnès Caille

Martine Reynaud-Gaubert

Abstract

BACKGROUND: Standard of care for interstitial lung disease (ILD) with a nonspecific interstitial pneumonia (NSIP) pattern proposes mycophenolate mofetil (MMF) as one of the first-step therapies while rituximab is used as rescue therapy. METHODS: In a randomised, double-blind, two-parallel group, pla...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!